Cronos Group Inc (CRON)
$5.77 0.25 (4.53%)
19:59 EDT CRON Stock Quote Delayed 20 Minutes
Previous Close $5.77
Market Cap 1.02B
PE Ratio -
Volume (Avg. Vol.) 4.31M
Day's Range 5.57 - 5.89
52-Week Range 4.00 - 18.42
Dividend & Yield N/A (N/A)
CRON Stock Predictions, Articles, and Cronos Group Inc News
- From InvestorPlace
- From the Web
The marijuana stock rebound in 2020 has run into a brick wall, but the fundamentals supporting the industry continue to improve.
Penny stocks are risky investments. But, these five penny stocks have realistic pathways to multi-bagger returns.
By Thomas Niel
Add in the Altria connection, and Cronos stock could be a big winner. But that's over a long time horizon. Until then, the best play is to wait for shares to reach a more reasonable valuation.
Cronos has delayed its quarterly and annual earnings report by at least two weeks while it conducts an audit of its financials. Until that audit is complete, the stock will likely underperform.
Aurora Cannabis continues to slump along with the rest of the cannabis industry, with Aurora stock down 81% over the past 12 months.
It may take awhile for it to materialize, but beaten-up Cronos stock could eventually turn into a multi-bagger for investors.
Tesla, Tilray, Cronos Group and the gold ETF (GLD) were our top stock trades for Wednesday. That said, here's a look at the charts.
Cronos Group reports its fourth-quarter and full-year results on Feb. 27. Owners of CRON stock shouldn’t expect much in the near term.
Thanks to favorable public sentiment and political tailwinds, the list of marijuana stocks to buy is both extensive and diverse.
Under conventional thinking, CRON stock can’t reach its full potential without the U.S. fully legalizing weed. But the “dumbed-down” CBD market is really what the American consumer desires, which benefits Cronos via its Lord Jones acquisition.
By Ian Cooper
With plenty of demand and legalization efforts, the long-term growth story is still very much intact with Organigram stock.
The 2020 presidential election will be a fierce battle. Here are the stocks to buy, depending on who wins the White House.
As a high-quality pick in a resurgent cannabis sector, CRON stock could be due for big returns in calendar 2020.
Options trading was hot in Bristol-Myers Squibb, Cronos and Canopy Growth stock on Tuesday. Here’s what the data suggests moving forward.
Matt McCall predicts that 2020 will be a better year for U.S. cannabis stocks. He's also calling for a big rally in bitcoin.
It’s unlikely to be the next Netflix or Microsoft, but Canopy Growth stock has made the case for today’s investors to take a nibble
Cannabis stocks have taken a huge hit in 2019 and will likely remain volatile while the industry goes through its growing pains. Long-term cannabis bulls can consider mitigating their portfolio risk by going long top legal cannabis producers and short CBD-focused stocks.
Navellier RatingsPowered by Portfolio Grader